Advanced bio-implants for breast cancer-related lymphedema: pioneering implantable lymphatic regeneration devices

To the Editor, Lymphedema is a chronic condition characterized by the accumulation of protein-rich fluid in the interstitium, causing edema, skin discoloration, and decreased motility of limbs. Infections, trauma, cancers, or radiotherapy for cancer treatment (most commonly for breast cancer) can cause obstruction in the lymphatic system, leading to secondary edema1. Breast cancer-related lymphedema (BCRL) is a serious and debilitating complication of breast cancer. A total of 15.5% of breast cancer survivors and up to 60% of women treated for breast cancer develop BCRL globally2. At the early disease stage, lymphedema is managed through conservative and surgical techniques that allow lymph volume reduction of up to 60%3. Additionally, novel regenerative techniques such as implant-based breast reconstruction (IBBR) and the use of biomaterials have shown declining trends toward BCRL4,5. Biomaterials such as nanofibrillar collagen scaffolds (NCSs) and silicone tubes (STs) reduce lymphedema by stimulating lymphangiogenesis and by creating an alternative channel for fluid drainage4. New lymphatic regeneration techniques, such as bioengineered lymphatic grafts, immunomodulation, stem cell, and growth factor-based therapies, have emerged as potential treatment options for post-surgical lymphedema6. A retrospective study comparing patients with IBBR and without reconstruction demonstrated a reduced incidence of lymphedema (8% vs. 13%) in post-mastectomy patients. Additionally, this study showed that patients with IBBR were less likely to develop upper limb swelling and to undergo physical therapy (61% vs. 73%) for lymphedema5. Results from recent studies suggest that bioimplants demonstrate promising efficacy in lymphedema management. For example, a systematic review regarding the implantation of two biomaterials showed an average post-implantation excess limb volume reduction of 10.7% and 1–2% with NCS, while the use of silicone tubing (ST) as a bioimplant reported a maximal volume reduction in the study within the first 2 weeks after ST implantation4. A more hybrid bioengineered therapeutic implant strategy includes a combined Adenoviral VEGF-C and lymph node transfer treatment, Lymfactin. Results of the early clinical trials have shown a 46% reduction in excess arm volume and a non-significant volume increase after garment removal at 12 months7. Despite such breakthroughs, many challenges remain. There is an insufficient number of studies available to draw meaningful long-term conclusions. The risk of bias in data for the included case reports and series, and the small number of available RCTs, indicate a lack of large, multicenter studies currently. Patient apprehension toward the invasive nature of the intervention and concerns about possible adverse effects hinder routine clinical implementation. The lack of uniform treatment protocols for the studies, along with heterogeneity and variation between the patients in each study, also limits the generalizability of the outcomes due to the lack of establishment of standard protocols5. Innovative methods of dealing with BCRL, like the use of bioengineered implants and regenerative therapies, have been revolutionizing treatment, but their acceptance in clinical practice is still a problem due to inadequacies in the existing literature1,5. High hopes are built on evidence showing volume reduction and better patient conditions; however, issues such as protocols not being uniform, large-scale studies being limited, and patients worrying about the procedure being too invasive are still present. To move the field forward, it is imperative that researchers conduct rigorous multicenter trials, establish standardized treatment guidelines, and perform long-term follow-up studies so that strong evidence supports the widespread adoption of these state-of-the-art interventions, which will eventually lead to better patient care and outcomes in lymphedema management3,6. In conclusion, advanced bioimplants for BCRL represent a promising alternative to current lymphedema management strategies but are under-represented in the mainstream research literature currently and therefore warrant the initiation of multidisciplinary trials4. Further multicenter studies with prolonged follow-up and detailed data reporting are required to assess the efficacy and safety of bioimplants and to enhance the generalizability and development of standard protocols for routine implementation. The early clinical results hold considerable promise for long-term effectiveness without significant adverse effects thus far.